HLK 6003
Alternative Names: HLK-6003Latest Information Update: 09 Dec 2024
Price :
$50 *
At a glance
- Originator HLK Pharmacin
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Melanosis
Most Recent Events
- 04 Oct 2024 HLK 6003 is available for licensing as of 04 Oct 2024. https://pharmacin.com/#section02
- 04 Oct 2024 HLK has patent protection for its technology (HLK Pharmacin pipeline, October 2024)
- 04 Oct 2024 Early research in Melanosis (unspecified route) before October 2024 (HLK Pharmacin pipeline, October 2024)